Cancrinase 3750 IU

Cancrinase 3750IU Injection is a chemotherapy medication that contains Pegaspargase as its active ingredient. It is utilized in the treatment of Acute Lymphoblastic Leukemia (ALL), a form of blood cancer characterized by the uncontrolled growth of immature white blood cells, which hinders the production of healthy blood cells. When used in conjunction with other chemotherapy drugs, this treatment can enhance the likelihood of remission and improve long-term survival rates for individuals diagnosed with ALL. It is especially beneficial for children with ALL, as they tend to have higher rates of remission and overall survival when this drug is part of their treatment regimen.

Typically, Cancrinase 3750IU Injection is administered alongside other chemotherapy agents for the treatment of ALL, particularly in patients who have not responded to previous therapies or who have experienced a relapse following initial treatment. Patients may experience glucose intolerance as a side effect of Cancrinase 3750IU Injection. If you encounter severe headaches, abdominal discomfort, excessive thirst, or significant allergic reactions while using this medication, it is important to contact your healthcare provider. Additionally, individuals with a history of kidney or pancreatic issues should consult their healthcare professional before starting this treatment.